|
Market Cap (17-May) $1,668,273,536 (454th) |
Close (30-Jun) $12.25 |
Volume (30-Jun) 261,029 |
Shortsold (5-May) 7,255,072 (5.76%) (39th) |
|
52w High $24.00 |
52w Low $8.61 |
P/E 76.34 |
EPS 1.09 |
NEU released this announcement to the ASX on 28 April 2023, 9:29. The announcement is not marked as price sensitive, and is 5 page(s) in length and 1MB in size.
You can view all announcements from NEU and see how they appear on a price chart on the announcements page.
At the date of this announcement, NEU was 0.677% short sold according to ASIC data. It was ranked the 287th most shorted stock on the ASX. It is now ranked as the 39th most shorted stock on the ASX with 5.756% of total shares short sold as of the latest reported data (05 May 2025).
| Other Recent Announcements from NEU | |
|---|---|
| Neuren completes enrolment in Phelan-McDermid Phase 2 trial | 30 June 2023, 9:36 |
| Neuren opens first site in US for Prader-Willi Phase 2 trial | 28 June 2023, 9:55 |
| Change of Director's Interest Notice | 14 June 2023, 18:44 |
| Virtual AGM online guide | 28 April 2023, 9:29 |
| Q1 2023 quarterly activity and cash flow report | 28 April 2023, 9:24 |
| Appendix 4G | 27 April 2023, 9:23 |
| 2022 Annual Report to shareholders | 27 April 2023, 9:21 |
You must be logged in to post a reply.
Neuren Pharmaceuticals 